Vaccine News: NIAID-Funded Adjuvant Improves Typhoid Vaccine Candidate in Animal Studies

National Institute of Allergy and Infectious Diseases sent this bulletin at 08/18/2022 11:12 AM EDT

Thursday, August 18, 2022

NIAID-Funded Adjuvant Improves Typhoid Vaccine Candidate in Animal Studies

Bacteria that cause typhoid fever shown under a microscope with red flagellar stain

The bacteria that cause typhoid fever are shown under a microscope with a red flagellar stain. Credit: Microbewriter, CC BY-SA 4.0

An investigational typhoid vaccine containing an adjuvant developed with NIAID funding may overcome some of the shortcomings of available typhoid vaccines, according to a paper published in the journal Vaccine. Although several kinds of typhoid vaccines are available, one that is inexpensive and easy to manufacture, and that provides robust and durable protection for people of all ages—especially very young children—remains elusive.

National Institute of Allergy and Infectious Diseases | National Institutes of Health

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).